Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Idera Pharmaceuticals has received notification from the Food and Drug Administration (FDA) to carry on with a Phase 2 clinical trial of IMO-3100 in patients with psoriasis.
Subscribe to our email newsletter
IMO-3100 is a dual antagonist of Toll-like receptor (TLR) 7 and TLR9, which is indicated as a therapy for autoimmune and inflammatory diseases.
In July 2011, the company submitted a Phase 2 protocol to evaluate IMO-3100 in patients with psoriasis over a 12-week treatment period, which was put on clinical hold by the FDA.
In October 2011, the company submitted a new Phase 2 protocol to evaluate IMO-3100 in patients with psoriasis over a 4-week treatment period, which led to notification of FDA authorization to proceed.
Idera chairman and CEO Sudhir Agrawal said the company is geared up to conduct Phase 2 trial of dual-TLR antagonist to treat autoimmune diseases and are likely to initiate the study in the first half of 2012.